Advertisement
Canada markets open in 8 minutes
  • S&P/TSX

    21,516.90
    -94.40 (-0.44%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • CAD/USD

    0.7298
    +0.0001 (+0.02%)
     
  • CRUDE OIL

    82.10
    +0.53 (+0.65%)
     
  • Bitcoin CAD

    89,825.82
    +585.52 (+0.66%)
     
  • CMC Crypto 200

    1,368.13
    -14.53 (-1.05%)
     
  • GOLD FUTURES

    2,350.90
    +4.00 (+0.17%)
     
  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     
  • 10-Yr Bond

    4.2710
    +0.0540 (+1.28%)
     
  • NASDAQ futures

    19,980.25
    +61.00 (+0.31%)
     
  • VOLATILITY

    12.55
    +0.07 (+0.56%)
     
  • FTSE

    8,238.34
    +33.23 (+0.40%)
     
  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     
  • CAD/EUR

    0.6805
    +0.0018 (+0.27%)
     

DIAGNOS Announces Grant of Stock Options

Diagnos Medical
Diagnos Medical

BROSSARD, Quebec, Feb. 10, 2023 (GLOBE NEWSWIRE) -- February 10, 2023 – Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces the grant of an aggregate number of 1,275,000 stock options to its officers, employees, consultants and directors.

Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price of these stock options has been established at $0.425 per share. The expiry date to which these stock options can be exercised has been fixed to February 10, 2028.

The stock options remain subject to the approval of the TSX Venture Exchange.

ADVERTISEMENT

All monies quoted in this press release shall be stated and paid in lawful money of Canada.

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.com and www.sedar.com.

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.ca